Obesity Drugs Remain Private as Public Sector Awaits State Review
Audio narration · Coming soon
WHO-backed obesity medicines are currently unavailable to public sector patients. This situation persists as the state has yet to conduct a review for a potential public rollout of these drugs.
Why this matters
PRISM scored this story 50/100 for interest.
Originally published by gnews